Outlook Therapeutics (OTLK) Sees Strong Trading Volume

Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares saw unusually-strong trading volume on Monday . Approximately 6,324,501 shares were traded during mid-day trading, an increase of 2,013% from the previous session’s volume of 299,311 shares.The stock last traded at $1.04 and had previously closed at $0.92.

Separately, ValuEngine lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th.

ILLEGAL ACTIVITY WARNING: “Outlook Therapeutics (OTLK) Sees Strong Trading Volume” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2019/02/11/outlook-therapeutics-otlk-sees-strong-trading-volume.html.

Outlook Therapeutics Company Profile (NASDAQ:OTLK)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

See Also: Understanding Analyst Ratings

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit